{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:25:22Z","timestamp":1794349522401,"version":"4.9.0"},"reference-count":214,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002767","name":"China Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2025JK2004"],"award-info":[{"award-number":["2025JK2004"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013385","name":"National Science and Technology Program during the Twelfth Five-year Plan Period","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023ZD0506105"],"award-info":[{"award-number":["2023ZD0506105"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2026ZD0555902"],"award-info":[{"award-number":["2026ZD0555902"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117697","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:57:13Z","timestamp":1790110633000},"page":"117697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade"],"prefix":"10.1016","volume":"29","author":[{"given":"Xiaodong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8033-0294","authenticated-orcid":false,"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117697_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117697_bib4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117697_bib21","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib22","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib24","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib28","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117697_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib30","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib33","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib34","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.isci.2026.117697_bib35","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117697_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117697_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte\u2013Associated Antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117697_bib40","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.176.6.1595","article-title":"Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes","volume":"176","author":"Linsley","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117697_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117697_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in Regulatory T Cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117697_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117697_bib48","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117697_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117697_bib50","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA Is an Immune Checkpoint Molecule for Human T Cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.7716543","article-title":"Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells","volume":"268","author":"Colonna","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117697_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib55","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib56","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117697_bib57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib60","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib61","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 Control over Foxp3+ Regulatory T Cell Function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117697_bib65","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117697_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib67","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib68","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib69","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","article-title":"Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front","volume":"182","author":"Sch\u00fcrch","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib71","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib72","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccell.2024.04.010","article-title":"Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis","volume":"42","author":"Gupta","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117697_bib74","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib75","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-17-0256","article-title":"TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence","volume":"7","author":"Reuben","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117697_bib76","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna, C.","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117697_bib77","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib78","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib79","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117697_bib80","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti\u2013CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117697_bib81","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib82","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib84","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non\u2013Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib85","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib86","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117697_bib87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jnci\/djae297","article-title":"First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors","volume":"117","author":"Othus","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.isci.2026.117697_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13942-8","article-title":"Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues","volume":"7","author":"Parra","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117697_bib89","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-20-2000","article-title":"Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell\u2013Level PI3K Pathway Activation","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002197","article-title":"Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study","volume":"9","author":"Taube","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib91","doi-asserted-by":"crossref","first-page":"8496","DOI":"10.1038\/s41598-024-58372-5","article-title":"Quantitative performance assessment of Ultivue multiplex panels in formalin-fixed, paraffin-embedded human and murine tumor specimens","volume":"14","author":"Ram","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117697_bib92","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib93","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib94","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","volume":"29","author":"Adam","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib95","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jtho.2019.08.2503","article-title":"Impact of Specimen Characteristics on PD-L1 Testing in Non\u2013Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations","volume":"14","author":"Gagn\u00e9","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib96","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib97","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jtho.2018.04.017","article-title":"PD-L1 Expression Heterogeneity in Non\u2013Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections","volume":"13","author":"Munari","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib98","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib99","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41592-022-01480-9","article-title":"Benchmarking spatial and single-cell transcriptomics integration methods for transcript distribution prediction and cell type deconvolution","volume":"19","author":"Li","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.117697_bib101","article-title":"Systematic benchmarking of imaging spatial transcriptomics platforms in FFPE tissues","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib103","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib104","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib105","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An Immune Atlas of Clear Cell Renal Cell Carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib106","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum","volume":"332","author":"Bendall","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib107","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib110","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117697_bib111","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib112","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117697_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121867","article-title":"A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies","volume":"3","author":"Ivison","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.117697_bib114","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nmeth.2365","article-title":"Critical assessment of automated flow cytometry data analysis techniques","volume":"10","author":"Aghaeepour","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.117697_bib115","doi-asserted-by":"crossref","DOI":"10.1038\/srep20686","article-title":"Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium","volume":"6","author":"Finak","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117697_bib116","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1038\/s41467-023-40631-0","article-title":"Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy","volume":"14","author":"Leung","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68468-3","article-title":"Standardization procedure for flow cytometry data harmonization in prospective multicenter studies","volume":"10","author":"Le Lann","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117697_bib118","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1038\/s41467-021-27150-6","article-title":"scCODA is a Bayesian model for compositional single-cell data analysis","volume":"12","author":"B\u00fcttner","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib119","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41587-019-0206-z","article-title":"Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion","volume":"37","author":"Satpathy","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117697_bib120","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.08.043","article-title":"Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib121","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117697_bib122","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41587-020-0469-4","article-title":"Benchmarking single-cell RNA-sequencing protocols for cell atlas projects","volume":"38","author":"Mereu","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117697_bib123","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.117697_bib124","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.celrep.2015.12.021","article-title":"Simultaneous Multiplexed Measurement of RNA and Proteins in Single Cells","volume":"14","author":"Darmanis","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117697_bib125","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nmeth.4437","article-title":"Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations","volume":"14","author":"van den Brink","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.117697_bib126","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13059-019-1830-0","article-title":"Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses","volume":"20","author":"O\u2019Flanagan","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.isci.2026.117697_bib127","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41467-021-21038-1","article-title":"A practical solution to pseudoreplication bias in single-cell studies","volume":"12","author":"Zimmerman","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib128","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1038\/s41467-021-25960-2","article-title":"Confronting false discoveries in single-cell differential expression","volume":"12","author":"Squair","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13059-019-1850-9","article-title":"A benchmark of batch-effect correction methods for single-cell RNA sequencing data","volume":"21","author":"Tran","year":"2020","journal-title":"Genome Biol."},{"key":"10.1016\/j.isci.2026.117697_bib130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-021-01336-8","article-title":"Benchmarking atlas-level data integration in single-cell genomics","volume":"19","author":"Luecken","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.117697_bib131","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41587-019-0392-8","article-title":"Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas","volume":"38","author":"Moncada","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117697_bib132","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41587-021-01044-w","article-title":"Cell segmentation in imaging-based spatial transcriptomics","volume":"40","author":"Petukhov","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117697_bib133","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1055-9965.EPI-10-0097","article-title":"Analytic variability in immunohistochemistry biomarker studies","volume":"19","author":"Anagnostou","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.isci.2026.117697_bib134","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-020-01378-4","article-title":"Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer","volume":"23","author":"Sanchez","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fonc.2019.00415","article-title":"Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials","volume":"9","author":"Gadalla","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001631","article-title":"PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy","volume":"8","author":"Simon","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib137","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.117697_bib138","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib139","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41389-023-00482-2","article-title":"Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade","volume":"12","author":"Zhang","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.isci.2026.117697_bib140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007180","article-title":"Single-cell sequencing on CD8(+) TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer","volume":"11","author":"Komuro","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib141","article-title":"Pan-cancer mapping of single CD8(+) T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","volume":"5","author":"Tooley","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.117697_bib142","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib143","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed Death-Ligand 1 Expression and Response to the Anti\u2013Programmed Death 1 Antibody Pembrolizumab in Melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib144","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117697_bib145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib146","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib147","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib Clinical Trial of Sabatolimab, an Anti\u2013TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti\u2013PD-1 Antibody, in Advanced Solid Tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib148","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","article-title":"Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma","volume":"26","author":"Fairfax","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib151","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib152","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1038\/s41591-025-04032-8","article-title":"Adjuvant nivolumab and relatlimab in stage III\/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib153","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib154","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti\u2013Programmed Death-1\/Programmed Death Ligand 1 Therapy: Results From the Phase I\/IIa RELATIVITY-020 Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009773","article-title":"Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020","volume":"13","author":"Ascierto","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib156","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2009.22.3701","article-title":"Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges","volume":"27","author":"Mandrekar","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib157","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/1078-0432.CCR-13-2698","article-title":"Comparison of Statistical Analysis Plans in Randomize-All Phase III Trials with a Predictive Biomarker","volume":"20","author":"Matsui","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib158","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1158\/1078-0432.CCR-08-0288","article-title":"Randomized Phase III Clinical Trial Designs for Targeted Agents","volume":"14","author":"Hoering","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117697_bib160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib161","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1\u2013Based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib162","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib163","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018306","article-title":"Decreased Absolute Lymphocyte Count and Increased Neutrophil\/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"9","author":"Drobni","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.isci.2026.117697_bib164","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","article-title":"Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor\u2013Induced Myocarditis","volume":"4","author":"Vasbinder","year":"2022","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.isci.2026.117697_bib165","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"JACC (J. Am. Coll. Cardiol.)"},{"key":"10.1016\/j.isci.2026.117697_bib166","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of Antithyroid Antibodies in Checkpoint Inhibitor\u2013Associated Thyroid Immune\u2013Related Adverse Events","volume":"107","author":"Muir","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2026.117697_bib167","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline","volume":"108","author":"Zhou","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2026.117697_bib168","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib169","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2026.117697_bib170","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117697_bib171","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib172","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s43018-023-00572-5","article-title":"Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer","volume":"4","author":"Sung","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib173","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012414","article-title":"Innate and adaptive immune features associated with immune-related adverse events","volume":"13","author":"Khan","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib174","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib175","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib176","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","article-title":"Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study","volume":"22","author":"Fonseca","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2026.117697_bib177","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2026.117697_bib178","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117697_bib179","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib180","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117697_bib181","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune Checkpoint Inhibitor Outcomes for Patients With Non\u2013Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib182","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib183","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib184","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non\u2013Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib185","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib187","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117697_bib188","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib189","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib190","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib191","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117697_bib192","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41392-024-02060-3","article-title":"Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)","volume":"9","author":"Ai","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117697_bib193","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.isci.2026.117697_bib194","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1038\/s41591-026-04502-7","article-title":"Generalizable AI predicts immunotherapy outcomes across cancers and treatments","volume":"32","author":"Shen","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib195","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/s41467-024-46150-w","article-title":"Data leakage inflates prediction performance in connectome-based machine learning models","volume":"15","author":"Rosenblatt","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib196","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib197","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2026.117697_bib198","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1073\/pnas.102102699","article-title":"Selection bias in gene extraction on the basis of microarray gene-expression data","volume":"99","author":"Ambroise","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117697_bib199","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/s41467-019-10656-5","article-title":"Establishing microbial composition measurement standards with reference frames","volume":"10","author":"Morton","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117697_bib200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","article-title":"Differential abundance testing on single-cell data using k-nearest neighbor graphs","volume":"40","author":"Dann","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117697_bib201","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/sim.9713","article-title":"A comparison of two approaches to dynamic prediction: Joint modeling and landmark modeling","volume":"42","author":"Li","year":"2023","journal-title":"Stat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib202","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1177\/0962280218811837","article-title":"Individual dynamic predictions using landmarking and joint modelling: Validation of estimators and robustness assessment","volume":"28","author":"Ferrer","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.isci.2026.117697_bib203","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41591-024-02905-y","article-title":"Development and validation of a new algorithm for improved cardiovascular risk prediction","volume":"30","author":"Hippisley-Cox","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib204","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070918","article-title":"Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study","volume":"379","author":"Archer","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2026.117697_bib205","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1002\/sim.8959","article-title":"Individual participant data meta-analysis for external validation, recalibration, and updating of a flexible parametric prognostic model","volume":"40","author":"Ensor","year":"2021","journal-title":"Stat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib206","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2021.03.025","article-title":"Internal-external cross-validation helped to evaluate the generalizability of prediction models in large clustered datasets","volume":"137","author":"Takada","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.isci.2026.117697_bib207","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2026.117697_bib208","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2026.117697_bib209","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0895-4356(03)00120-3","article-title":"External validity of predictive models: a comparison of logistic regression, classification trees, and neural networks","volume":"56","author":"Terrin","year":"2003","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.isci.2026.117697_bib210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2020.03.002","article-title":"Logistic regression was as good as machine learning for predicting major chronic diseases","volume":"122","author":"Nusinovici","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.isci.2026.117697_bib211","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1002\/sim.9025","article-title":"Minimum sample size for external validation of a clinical prediction model with a binary outcome","volume":"40","author":"Riley","year":"2021","journal-title":"Stat. Med."},{"key":"10.1016\/j.isci.2026.117697_bib212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib213","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117697_bib214","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/jamia\/ocx030","article-title":"Calibration drift in regression and machine learning models for acute kidney injury","volume":"24","author":"Davis","year":"2017","journal-title":"J. Am. Med. Inform. Assoc."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226030786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226030786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:37:09Z","timestamp":1794346629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226030786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":214,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226030786"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117697","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117697"}}